Ferritin — one blood test — tells you whether iron is the right move. Under thirty, the gains land within weeks: energy first, then attention, then hair months later. Above fifty, you'll spend money building toward an iron overload you can't undo. The protocol the evidence now backs — a single morning dose every other day — is also gentler on the stomach than the daily-with-meals advice most prescribers grew up with.
The version of you that's been writing off afternoons as personality — sleepy after lunch, unable to push through the three-o'clock slump, breathless on stairs that didn't used to count — may not have a personality problem at all. In a randomised trial of fatigued women whose ferritin was under fifty, four weeks of oral iron cut fatigue by twenty-nine percent against thirteen percent on placebo Verdon 2003. Among the women whose ferritin was under fifteen in a separate trial, eighty-two percent said they felt better, versus forty-seven percent on placebo Krayenbuehl 2011.
The decision turns on one blood test. Ferritin is the protein your body stores iron inside, and the blood level tracks the size of the store. Under thirty micrograms per litre is the cutoff most current guidelines use to call iron deficiency, regardless of sex or whether your haemoglobin looks normal Snook 2021. That picture — depleted ferritin with a blood count that still reads normal — is iron deficiency without anaemia, the version most often missed. Above fifty, you almost certainly do not need a supplement — and taking one anyway adds iron you cannot get rid of. The grey zone between is where the literature still argues.
For people who do land low, what comes back is consistent across studies: energy first, attention next, hair and nails over months. Cognitive tasks — attention, processing speed, working memory — sharpen within weeks; the brain runs on iron-dependent enzymes, and depleted stores blunt the dopamine system the prefrontal cortex relies on Pasricha et al. 2021. Hair shedding from telogen effluvium slows once stores rebuild; new growth takes another two to three months to reach the scalp Trost et al. 2006. Restless legs at night respond when stores are low even if the rest of the bloodwork looks fine — brain iron tracks separately from blood iron, and the cutoff in restless-legs medicine is a higher ferritin under seventy-five Trenkwalder et al. 2017.
Why every other day beats every day
The body has no way to throw iron out. Sweat, shed skin, and sloughed-off gut cells together lose about one to two milligrams a day — that is the entire excretion budget. Everything else stays. So the body controls iron by controlling how much it absorbs from food and supplements, and the hormone running that control is hepcidin.
The mechanism is simple. Hepcidin locks the door iron uses to leave the gut cell and enter the bloodstream. When your stores are high, hepcidin rises and absorption falls. When stores are low, hepcidin falls and absorption rises. The hormone updates fast — and that update window is the lever that decides how to take iron.
A single oral iron dose of sixty milligrams of elemental iron or more triggers a hepcidin spike that lasts about twenty-four hours Moretti et al. 2015. Take a second dose four hours later and the gut absorbs thirty-five to forty-five percent less of it — your morning pill closed the door on your evening one. The "ferrous sulfate three times a day with meals" protocol older guidelines still recommend is fighting itself.
The clinical conclusion is now picked up in current guidelines Snook et al. 2021: one dose, single morning, every other day. Same total iron absorbed from fewer pills, with less of the nausea that makes people quit halfway through.
The protocol
Order a ferritin and a complete blood count before the first pill. If ferritin is under thirty — or under seventy-five and you have restless legs at night — supplement. If it is between thirty and fifty and you are symptomatic (fatigue, hair shedding, exertional breathlessness with no other explanation), supplement and retest at six weeks. If it is above fifty, the answer is no.
If you take a proton-pump inhibitor — omeprazole, esomeprazole, lansoprazole, any of the long-term reflux pills — tell whoever is prescribing your iron. Those drugs cut the stomach acid that converts iron to the absorbable form, and oral repletion is slower and often incomplete while you are on them Snook et al. 2021. Intravenous iron — a single thousand-milligram infusion of ferric carboxymaltose or an equivalent — is the alternative when oral does not work, does not absorb, or you need stores rebuilt fast (heart failure with iron deficiency, inflammatory bowel disease, severe anaemia close to a planned operation).
Where this goes wrong
The pattern of how people get iron supplementation wrong is consistent enough to list:
- Self-prescribing without a ferritin. Fatigue is non-specific. Roughly one in three fatigued adults turns out to be iron-deficient — the rest have something else going on, and a few of them have a genetic condition that makes the supplement actively dangerous (see the next section). Without the lab number, you are guessing.
- Daily dosing. Hepcidin closes the door for about twenty-four hours after each dose, so daily delivery overlaps its own absorption window. Every other day is better-absorbed and gentler on the gut Moretti et al. 2015.
- Coffee or tea with the pill. Tannins bind iron in the gut. One cup of coffee within an hour of dosing can cut absorption by half — repletion that should take three months drags into six for the cost of a habit you could shift by an hour.
- Calcium at the same time. Milk, yogurt, and calcium supplements compete for the same transporter. Less dramatic than coffee, still measurable.
- Stopping when the blood count looks good. Haemoglobin normalises in four to six weeks. Ferritin takes three to six months. Quit when the haemoglobin is back and stores are still empty, and symptoms return within a year Camaschella 2015.
- Pushing through high-dose daily ferrous sulfate. The nausea and constipation are real and account for most quit-rates. Cutting to every other day or switching to bisglycinate solves more cases than "tough it out" ever did.
When iron is the wrong move
The safety asymmetry that defines this entry: the body has no way to remove iron once it is in. Excess vitamin C floods out in urine. Excess B-vitamins do the same. Iron does not. So the people who should not supplement are not a marginal group — they are anyone whose stores are normal or high to begin with, and a smaller group whose biology removes the absorption brake entirely.
Beyond haemochromatosis: people on chronic transfusion programmes, with thalassemia, with sideroblastic anaemia, or with active untreated infections should not take iron without a haematologist's input. And the practical floor that applies to every household: iron pills are among the most common pediatric poisonings. The dose that helps a deficient adult is acutely toxic to a small child. Lock the bottle the way you would paracetamol.
What comes back, and when
The timeline, for an adult with low ferritin who starts the alternate-day protocol:
- Weeks one and two. Haemoglobin starts climbing, typically about ten grams per litre per month if absorption is working. In the most-deficient, a subtle energy lift is already detectable.
- Weeks four to eight. Fatigue noticeably softens Verdon et al. 2003. Your partner stops asking if you're coming down with something. The afternoon you used to write off as a wash is back on the table. Climbing a flight of stairs stops being a small event.
- Months two to four. Attention and processing speed sharpen — work that took an hour takes forty minutes again. For the restless-legs subset, the night-time twitch settles Trenkwalder et al. 2017. Hair shedding in the shower drain visibly drops; new growth is in the scalp but too short to see.
- Months three to six. Ferritin rebuilds into a comfortable range. Brittle nails stop splitting. The new hair pushes past the original line and the part visibly thickens.
- Year one and beyond. For menstruating women, the deficit can come back unless heavy bleeding or diet shifted. An annual ferritin is a cheap check; another short course if it drifts down.
The honest version: in someone who was genuinely deficient, this is among the most reliably-felt nutritional interventions there is. In someone who wasn't, you will feel nothing — and your stores will keep climbing toward a problem you cannot undo.
Adjacent topics worth knowing about: iron deficiency in pregnancy (different target, different dose, different protocol), heavy menstrual bleeding as the upstream driver of recurrent deficiency in women, the vegetarian iron equation (plant-source iron is less absorbable and competes with phytates), and the heart-failure iron deficiency syndrome where intravenous iron has its own outcome evidence. Each warrants its own entry.
- — Tannins in coffee and tea block iron absorption, so keep your iron pill an hour clear of your morning cup.
- — Low ferritin with normal hemoglobin is the classic case where iron helps — energy back within weeks.
- — Restless legs is one of the clearest reasons to fix low iron — replacing it is the first treatment to try.
- — Take iron with a vitamin-C source and you absorb noticeably more of it; a free upgrade.
- — Heavy periods from fibroids are a leading reason women run low. Fix the bleeding and the iron, not just one.
- — Never start iron blind — a ferritin test tells you whether you need it, since the body can't dump excess.
- — If your ferritin is low, a weekly portion of liver delivers heme iron your gut absorbs far better than plant sources.
- — Heavy periods are the single most common reason iron stores run dry in menstruating adults — treat the bleeding, not just the iron.
- — The reason to test before supplementing: in hemochromatosis, extra iron speeds a slow poisoning.
- — Before supplementing iron, the MCV/RDW grid tells you whether iron is actually what's behind the low count.
- — If your iron is low and your plate is plant-heavy, phytic acid may be locking the iron away; prep matters.
- — Take iron well away from thyroid medication, or it'll blunt the dose.
Substance and claimed effects
Iron supplementation in adults — oral ferrous salts (sulfate, fumarate, gluconate, bisglycinate) and, in clinical settings, intravenous preparations (ferric carboxymaltose, iron sucrose, ferric derisomaltose). Claimed effects in deficient adults: reduction of fatigue, restoration of exercise capacity, improvement in cognitive function, regrowth of hair lost to telogen effluvium, and resolution of restless legs symptoms Camaschella 2015 Pasricha et al. 2021. The substance's defining biological property: humans have no regulated excretion pathway for iron — losses occur only through bleeding, menstruation, and shed enterocytes/skin (≈1–2 mg/day) — so absorption is the only homeostatic lever and hepcidin is its master regulator Pasricha et al. 2021. The article covers indications (when to supplement), absorption mechanics, the hepcidin-driven case for alternate-day single-dose protocols, and the consequences of correcting deficiency across energy, exercise, cognition, hair, sleep (via restless legs), and mood.
Evidence by addressing question
evidence (indications and effect across dimensions)
Iron-deficiency anemia (IDA). Settled territory. Oral iron salts are first-line; intravenous iron for malabsorption, intolerance, or rapid repletion needs. Replication is dense: hundreds of RCTs, Cochrane-level meta-analyses, guideline-backed (BSG 2021, WHO) Snook et al. 2021 Camaschella 2015. Hemoglobin recovery starts within 1–2 weeks; ferritin repletion takes 3–6 months Snook et al. 2021.
Non-anemic iron deficiency (NAID, low ferritin with normal Hb). The contested zone, but the literature has converged. Verdon et al. 2003 (BMJ, n=144 women aged 18–55 with unexplained fatigue): four weeks of 80 mg/day elemental iron reduced fatigue by 29% versus 13% on placebo; effect concentrated in women with ferritin ≤50 µg/L Verdon et al. 2003. Krayenbuehl et al. 2011 (Blood, n=90 premenopausal women, hemoglobin ≥120 g/L, ferritin ≤50): IV iron sucrose 800 mg vs placebo — fatigue improvement was striking in the subgroup with ferritin ≤15 µg/L (82% improved vs 47% placebo, p=0.03) and modest above that Krayenbuehl et al. 2011. Vaucher et al. (CMAJ 2012) replicated in women with ferritin <50: significant fatigue reduction with oral iron at 12 weeks. The picture: deeper deficiency = larger effect; the marginal-ferritin (30–50) tier shows real but smaller signal.
Exercise capacity. In non-anemic iron-depleted women, supplementation improves submaximal endurance and time-trial performance; effect on V̇O2max is mixed and largely seen only when baseline soluble transferrin receptor is elevated (the tissue-deficiency marker) Pasricha et al. 2021. Brutsaert et al. (Am J Clin Nutr 2003): iron-depleted previously untrained women showed impaired aerobic adaptation that supplementation rescued. Mechanism is twofold: hemoglobin (oxygen delivery) and muscle myoglobin / mitochondrial cytochromes / TCA-cycle iron–sulfur enzymes (oxygen utilization). Effect sizes in elite athletes are smaller; the population that benefits most is sedentary-to-recreational with measurable depletion.
Cognition. In adults, the strongest signal is for attention, processing speed, and working memory in deficient subjects; effects on healthy iron-replete adults are negligible Pasricha et al. 2021. Murray-Kolb & Beard (Am J Clin Nutr 2007): in non-anemic iron-deficient women, supplementation improved cognitive task performance by ≈25% on tasks where baseline performance was depressed. Falkingham et al. (Nutr J 2010) meta-analysis: iron supplementation improves attention and concentration regardless of baseline iron status, and lifts IQ by ≈2.5 points in anemic subjects.
Hair. Telogen effluvium — diffuse hair shedding — is associated with low ferritin. Trost et al. 2006 (J Am Acad Dermatol, comprehensive review): five of six studies examining ferritin in women with hair loss found significantly lower ferritin in cases vs controls; the suggested threshold for relevance is ferritin <40 µg/L, with strongest effects below 30 Trost et al. 2006. A 2022 systematic review and meta-analysis confirmed the association across 10,000+ subjects; the magnitude is small in absolute terms (mean ferritin difference ≈18 ng/mL) but consistent in direction. Mechanism: iron-dependent ribonucleotide reductase drives matrix-keratinocyte proliferation; deficiency halts the anagen phase early.
Sleep (restless legs syndrome). RLS is the entry's only direct sleep link, and the mechanism is brain iron — substantia nigra ferritin is depressed in RLS patients even when serum ferritin is normal-ish. Trenkwalder et al. 2017 (Mov Disord): single 1000 mg ferric carboxymaltose vs placebo in RLS with non-anemic iron deficiency — significant symptom reduction at week 12 (IRLS score difference ≈4 points), no significant effect at week 4 (brain iron uptake is slow) Trenkwalder et al. 2017. Standard threshold: ferritin <75 µg/L or transferrin saturation <20% warrants iron in RLS, higher than the systemic-deficiency cutoff.
Mood. Weakest of the named effects. Cross-sectional links between low ferritin and depression / postpartum depression exist; randomized supplementation data is thinner. Falkingham 2010 meta found no significant effect on depression. The mood signal in supplementation trials may be a downstream consequence of fatigue relief rather than a direct CNS effect.
mechanism (hepcidin and the alternate-day case)
Hepcidin is the master regulator. It binds ferroportin — the only known cellular iron exporter — on enterocyte basolateral membranes and macrophages, triggers ferroportin internalization and degradation, and halts iron entry to plasma Pasricha et al. 2021. Plasma hepcidin rises in response to iron stores (negative feedback) and inflammation (IL-6 → STAT3); it falls with erythropoietic demand (erythroferrone) and hypoxia.
The clinically load-bearing finding: a single oral iron dose ≥60 mg of elemental iron raises plasma hepcidin within hours and keeps it elevated for ~24 hours, suppressing absorption of any subsequent dose taken in that window Moretti et al. 2015. Moretti et al. 2015 quantified this in iron-depleted women using stable-isotope tracers: fractional absorption from a second 60 mg dose taken 4 hours after the first dropped by 35–45% versus a no-prior-dose control. Twice-daily dosing therefore wastes the second dose.
Stoffel et al. 2017 (Lancet Haematol) extended to consecutive vs alternate days: 60 mg daily for 14 days vs alternate-day for 28 days (same total exposure). Cumulative iron absorption was 34% higher on the alternate-day arm (175 mg vs 131 mg absorbed, p=0.001), fractional absorption 21.8% vs 16.3% Stoffel et al. 2017. Stoffel et al. 2020 (Haematologica) reproduced the finding in iron-deficient anemic women (not just depleted): alternate-day dosing produced higher absorption with a non-significant trend toward fewer GI side effects Stoffel et al. 2020.
Mechanism: a single 60+ mg dose drives plasma iron and hepcidin up; hepcidin closes ferroportin for ~24h; giving 24h+ between doses lets hepcidin fall and ferroportin re-express, restoring absorption. The clinical implication: a single morning dose every other day is mechanistically and trialwise superior to daily and to split (BID) dosing. Multiple subsequent RCTs (including eClinicalMedicine 2023) have replicated the absorption result; equivalent-or-superior hemoglobin recovery with comparable or shorter time-to-repletion is now the consensus position in BSG 2021 and ASH draft 2024 guidelines Snook et al. 2021.
protocol
Diagnostic anchors. Iron deficiency is defined by depleted stores: ferritin is the workhorse. BSG/NICE/WHO cutoff for absolute deficiency is ferritin <30 µg/L regardless of sex; in inflammation (CRP elevated), ferritin is acute-phase-reactant and the cutoff shifts to <100 with transferrin saturation <20% Snook et al. 2021. Hemoglobin defines anemia (men <130 g/L, non-pregnant women <120 g/L per WHO). Soluble transferrin receptor (sTfR) is the tissue-deficiency marker, useful when ferritin is confounded by inflammation. RLS-relevant cutoffs are higher (<75 µg/L).
Repletion protocol. Oral ferrous sulfate 65 mg elemental iron (≈325 mg ferrous sulfate tablet) every other day, single morning dose on empty stomach, with 100–500 mg vitamin C or a glass of orange juice. Ferrous bisglycinate ≈25–28 mg elemental is a gentler alternative with similar absorption per mg. Avoid coffee, tea, dairy, calcium supplements, and antacids within 1–2 hours; PPIs and H2-blockers reduce gastric acid and impair non-heme iron absorption significantly. Duration: continue for 3 months after hemoglobin normalizes — to refill stores (ferritin) — typically 4–6 months total Snook et al. 2021 Camaschella 2015.
Monitoring. Recheck hemoglobin and ferritin at 6–8 weeks (hemoglobin rises ≥10 g/L by 4 weeks if absorption is working) and again at 3–6 months. Failure to respond → reassess for ongoing blood loss (GI workup in older adults), malabsorption (celiac, atrophic gastritis), or hepcidin disorders (chronic inflammation, IRIDA).
IV iron. Indicated when oral iron is intolerable, malabsorption is suspected, repletion needs are large or urgent (anemia of CKD, IBD, heart failure with iron deficiency, perioperative). Ferric carboxymaltose and ferric derisomaltose deliver 1000 mg in a single infusion; hypophosphatemia is a notable side effect of FCM.
contraindications
Hereditary hemochromatosis (HFE C282Y homozygote prevalence ≈1 in 200–300 in populations of Northern European ancestry; clinical penetrance lower, perhaps 10–30%). These individuals absorb iron unregulated due to low hepcidin; supplementation accelerates iron overload (cardiomyopathy, cirrhosis, arthropathy, diabetes). Routine iron supplementation without checking ferritin and transferrin saturation is the failure mode. Other iron-loading conditions: thalassemia syndromes, sideroblastic anemia, transfusion-dependent disorders.
Active infection. Iron is a growth factor for many pathogens; hepcidin's evolutionary role includes sequestering iron from invaders. Supplementation during acute febrile illness or untreated chronic infection (HIV, TB) carries risk in some populations.
The absence of an excretion pathway. The defining safety asymmetry of this entry. Unlike vitamin C, B-vitamins, or magnesium — where excess clears via urine — iron taken when stores are full simply accumulates. Acute overdose (especially in children with adult-dose pills) is among the most common pediatric poisonings; chronic over-supplementation in iron-replete adults raises markers of oxidative stress and, in genetically predisposed, hastens overload syndromes.
failure-modes
- Self-prescribing without testing. Fatigue is non-specific; only ~1 in 3 fatigued patients turns out to have low ferritin. Supplementation without baseline labs misses the diagnosis (or risks overload in genetic carriers).
- Daily or twice-daily dosing. Hepcidin's 24h refractory period means the second dose absorbs at 35–45% lower fraction Moretti et al. 2015. Same total exposure, less iron in.
- Coffee/tea timing. Tannins and polyphenols chelate non-heme iron; a cup of coffee within an hour of the dose can reduce absorption by 50–60%.
- Calcium co-ingestion. Milk, yogurt, calcium supplements compete at the DMT1 transporter — same mechanism, smaller effect than coffee.
- PPI use ignored. Reduced gastric acid impairs Fe³⁺ → Fe²⁺ reduction; non-heme iron absorption can fall by ≥50%. Heme iron is less affected but supplements are non-heme.
- Stopping when hemoglobin normalizes. Ferritin (stores) lags hemoglobin by months. Stopping at 6 weeks because the CBC looks good repopulates symptoms within a year.
- GI intolerance leading to abandonment. Daily high-dose ferrous sulfate causes nausea, constipation, dark stools in ≈30–40%. The alternate-day shift halves exposure and reduces side effects; bisglycinate is the rescue formulation.
stakes
What chronic iron deficiency feels like, week to year: persistent fatigue that doesn't improve with sleep; exertional breathlessness disproportionate to fitness; cold extremities; brittle nails (koilonychia at the severe end); hair shedding (telogen effluvium) typically lagging the deficiency event by 2–3 months; pica (ice-craving especially); restless legs at night; brain-fog and reduced exercise tolerance; menstrual heaviness that further depletes stores in a deficit loop Camaschella 2015. Untreated iron-deficiency anemia in heart failure raises hospitalization and mortality; in pregnancy, increases preterm delivery and low birth weight Pasricha et al. 2021.
payoff
What returns, on what timescale, given alternate-day oral supplementation in a deficient adult:
- Days 7–14: hemoglobin begins climbing ≈10 g/L per month if absorption is working; subtle energy lift may appear in severely deficient subjects.
- Week 4–8: fatigue scores meaningfully improve — Verdon's BMJ trial showed ≈29% reduction at 4 weeks Verdon et al. 2003; Krayenbuehl's most-deficient subgroup hit 82% improvement in fatigue at 12 weeks Krayenbuehl et al. 2011.
- Month 2–4: exercise capacity, cognition (attention, processing speed), restless legs symptoms normalize.
- Month 3–6: ferritin stores rebuild; hair regrowth becomes visible (new anagen hairs take 2–3 months to emerge); brittle nails resolve.
- Maintenance: in menstruating women, recurrent deficiency cycles unless dietary or menstrual contributors change. Periodic ferritin checks (annual) are reasonable.
The credibility range
Optimist case
Iron deficiency is the most prevalent micronutrient deficiency on earth, affecting ~30% of premenopausal women globally and a substantial minority of vegetarians, blood donors, athletes, and older adults Pasricha et al. 2021. The supplementation evidence is among the strongest in nutrition: 1000+ trials in IDA, multiple RCTs in non-anemic ID showing fatigue and cognitive benefit, mechanistic clarity (hepcidin biology), and a clean dose-response. The alternate-day single-dose protocol is one of the cleanest mechanism-to-protocol translations in nutritional medicine: a 2015 mechanistic finding (Moretti) became a 2017 absorption RCT (Stoffel), then a 2020 replication in anemic subjects (Stoffel), and is now in 2021 BSG guidelines. Cheap, oral, accessible, settled.
Skeptic case
The non-anemic supplementation case is softer than it looks. Verdon 2003 found a 13% placebo response on a 10-point fatigue VAS — fatigue is suggestible, and unblinding from GI side effects in iron arms is a known concern. Krayenbuehl's effect concentrated in the ferritin ≤15 subgroup (n=22), and the broader ≤50 cohort showed smaller and less consistent effects. The ferritin cutoff itself is contested: the WHO threshold of 15 µg/L (deficiency) and the BSG <30 µg/L are both defensible, but the upper range where "non-anemic deficiency" might warrant treatment (30–50, 50–75 for RLS) is increasingly an "indication creep" target for supplement marketing. Iron is not a benign intervention to take prophylactically — the absence of an excretion pathway is asymmetric — and the supplement industry's pitch to non-deficient women carries real downside in HFE carriers (1 in 100–200) and unknown long-term consequences of chronic mild over-exposure.
The author's call
Iron supplementation is high-leverage when indicated and harmful when not. The article should pivot on the test-first message: ferritin and TSAT determine whether you supplement; the alternate-day single-dose protocol is the evidence-aligned default; hemochromatosis screening is the safety floor. The energy and cognition payoffs are real and well-documented in deficient subjects; the temptation to extrapolate to non-deficient adults should be resisted. Evidence strength: 4/5 (strong for IDA and ferritin <30, moderate for the ferritin 30–50 zone, less settled for cognitive/exercise outcomes outside that). Controversy: 2/5 (mechanism and indication broadly agreed; ferritin cutoff and non-anemic threshold the live debate).
Stakeholder and incentive map
- Supplement industry: markets iron broadly to fatigued women without ferritin gating. Pushes higher doses, daily protocols (more pills sold), and proprietary formulations.
- Hematology / gastroenterology specialists: increasingly aligned on alternate-day single-dose oral iron, BSG 2021 guideline, IV iron in select indications (CKD, IBD, HF). Push back against undertreatment of iron deficiency (especially in heart failure, where the IRONMAN and AFFIRM-AHF trials drove uptake of IV iron).
- Primary care: historically prescribed ferrous sulfate 200 mg TID — high GI burden, lower absorption, high abandonment. Slow to adopt alternate-day.
- Hemochromatosis genetics advocacy: pushes for HFE genotyping in iron-loading workups; counter-pressure against routine over-supplementation.
- Athletic/coaching communities: sometimes over-supplement athletes prophylactically; "low ferritin" creep below evidence-supported thresholds.
Population variability
- Menstruating women: dominant deficiency population. Heavy menstrual bleeding (HMB) creates a deficit loop; iron repletion without addressing HMB recurs.
- Vegetarians/vegans: plant-source iron (non-heme) is less bioavailable; phytate-rich diets compound. Higher baseline supplementation indication.
- Blood donors: regular whole-blood donors deplete iron stores; many blood services now recommend iron supplementation for frequent donors.
- Older adults: iron deficiency in adults over 60 is GI bleeding until proven otherwise — supplementation without colonoscopy/EGD workup misses cancer Snook et al. 2021.
- Endurance athletes: exercise-induced hepcidin spike (IL-6-driven) post-exercise reduces absorption for 3–6 hours; mechanistic basis for taking iron in the morning, not post-training.
- HFE C282Y carriers/homozygotes: ~1 in 200 Northern European descent are homozygotes; routine iron screening before supplementation matters.
- Inflammation (CKD, IBD, obesity, infection): functional iron deficiency — hepcidin elevated by IL-6, iron locked away despite normal/high ferritin. Oral iron poorly absorbed; IV iron preferred.
Knowledge gaps
Where the "non-anemic supplementation for fatigue" threshold actually sits — ferritin 15 is well-supported, 30 plausibly, 50 increasingly thin, 75 (for RLS) genuinely contested. Whether long-term low-dose maintenance supplementation in menstruating women carries any cumulative risk (largely unstudied). Whether alternate-day protocols translate to comparable hemoglobin endpoints in shorter overall treatment durations (most absorption trials track absorption, not Hb endpoints over months; Düzen 2024 and the FORTE trial 2025 are filling this). Heme iron supplements (haemochrome) vs ferrous salts — hepcidin response differs, but head-to-head clinical outcome data is sparse. The intersection of common SSRI/PPI use and iron absorption in primary-care populations is undermapped.
Scope decisions. The brief named energy, exercise capacity, cognition, and hair as the consequences worth covering; all four landed in the body. Exercise capacity is folded into the evidence section's "energy first, attention next, hair and nails over months" bundle rather than getting its own section — the trial literature for non-anemic exercise effects is moderate (Brutsaert 2003, Burden 2015 review) and the felt-experience prose covers it adequately.
Mood scored 0, not 1. First-draft scored mood 1 (cross-sectional links between low ferritin and depression exist). Reduced to 0 on the body-coverage discipline: any felt mood lift in supplementation trials is downstream of fatigue relief, not an independent CNS effect (Falkingham 2010 meta found no effect on depression scales). Putting a dedicated mood paragraph in the body to "earn" a 1 would inflate the substance's reach; honest call is 0.
Action type. Picked decide rather than do because the test-first message is the entry's pivot — taking iron without knowing ferritin is the consistent failure mode and the absence of an excretion pathway makes self-prescription net-negative for non-deficient adults. decide captures the weigh-the-tradeoff posture better than do.
Cadence. course — repletion is a bounded 3–6 month course, not an indefinite daily habit. For menstruating women the course can recur, but each instance is a course.
Evidence score (4 vs 5). IDA treatment alone would justify a 5, but the entry covers more than that — the alternate-day protocol is supported by strong mechanistic and absorption RCTs (Moretti 2015, Stoffel 2017/2020) but hemoglobin-endpoint outcome trials are still accruing (FORTE 2025, eClinicalMedicine 2023). Non-anemic supplementation for fatigue is moderate-evidence (Verdon, Krayenbuehl, Vaucher) and ferritin-cutoff dependent. Averaging across the substance's full scope: 4 is honest, 5 would oversell the non-anemic case.
Beauty scores. beauty_direct is the hardest call — telogen effluvium hair-fall slows within weeks but visible regrowth is months out; the "topical, days to weeks" frame fits poorly. Settled on 1 over 2 because the within-weeks visible signal is real but small.
Ferritin cutoff. Used BSG/NICE <30 µg/L as the absolute cutoff and the 30–50 µg/L grey zone as conditional. WHO uses <15 µg/L for the deficiency definition but newer Mei/Lancet Global Health 2025 work argues for higher physiological thresholds. Kept the BSG-consistent number to align with current clinical practice rather than the academic frontier.
Excluded — separate-entry candidates.
- Iron deficiency in pregnancy — different target (ferritin >100 ideal), different dose, intersects with obstetric care; warrants its own entry.
- Heavy menstrual bleeding — upstream cause of recurrent iron deficiency in many women; deserves an entry covering the gyne workup and treatment options.
- Iron deficiency in heart failure — IV iron has a distinct outcome evidence base (AFFIRM-AHF, IRONMAN); the protocol and indication differ enough to merit a separate entry.
- HFE haemochromatosis — flagged as contraindication here; the full screening, monitoring, and therapeutic-phlebotomy story is its own entry.
- Restless legs syndrome — the iron-RLS link is one of several causal threads; a dedicated RLS entry should cross-reference here.
Future links. When the entries above land, the out-of-scope section should be re-wired to point at them directly.
Contraindications token choice. hemochromatosis was the load-bearing one. Did not add pregnancy or breastfeeding — iron is generally indicated in both, not contraindicated. Active infection is mentioned in the body but no closed-vocab token for it exists, so it stays inline.
Audience. Left fully open. Iron deficiency disproportionately affects premenopausal women, vegetarians, blood donors, and older adults — but the substance's relevance is genuinely universal once ferritin is checked, so audience-gating would mislead.
Iron
About ten to thirty dollars a year for the pills. The cost of testing is the bigger line item.
A pill every other morning for a few months, away from coffee. Two blood tests to bookend it.
The biggest lever this article pulls. People who'd written off afternoons as their normal often get them back.
Anemia treatment is rock-solid. The every-other-day protocol is newer but well-supported. Non-anemic supplementation is real but ferritin-dependent.
If your ferritin is genuinely low, the bone-tired floor lifts within weeks. If it isn't, you won't feel a thing.
Over three to six months, hair density, nail strength, and skin colour quietly come back in people who'd been running low.
In low-iron adults, attention sharpens and tasks that felt foggy clear up. Iron-replete people get nothing here.
If your hair has been shedding from a low-iron patch, supplementing slows the fall within weeks. Regrowth comes later.
Mostly matters at the edges — heart failure, pregnancy, severe deficiency. For a healthy adult with normal stores, no real lifespan dial.
Helps a specific group: people with restless legs whose iron is on the low side. Doesn't make most sleep better.